Report Description of the APAC Polycystic Ovarian Syndrome (PCOS/PCOD) Treatment Market

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for Polycystic Ovarian Syndrome Treatment Market


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Polycystic Ovarian Syndrome Treatment market


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy-based consulting analysis

APAC Polycystic Ovarian Syndrome (PCOS/PCOD) Treatment Executive Summary

Polycystic ovary syndrome (PCOS) is a common hormonal endocrine disorder that affects women of childbearing age (15 to 49 years). According to the Centers for Disease Control & Prevention (CDC), polycystic ovary syndrome (PCOS) is the most common cause of female infertility. Also, the prevalence of polycystic ovarian syndrome in adolescents based on the Rotterdam criteria was found to be 11.04%, based on the National Institute of Health criteria, it was 3.39%, and based on Androgen Excess and Polycystic Ovary Syndrome Society, it was 8.03%, worldwide. The increasing burden of PCOS and no targeted therapy for PCOS being available in the market creates a need to develop therapies to treat them

Market Size and Key Findings

The APAC Polycystic Ovarian Syndrome (PCOS / PCOD) Treatment Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 6.3% during the forecast period.

The Asia Pacific region including China and India accounted for the major population base. The administrations in these countries are aiming at controlling the increasing prevalence of PCOS by accomplishing programs that support the analysis & therapeutics of this disorder and the required modification in lifestyle. These aspects are likely to spur the Asia Pacific market in the future.



Market Dynamics

Market Growth Drivers Analysis

The prevalence of the PCOS disease are growing which is fuelling growth of the global polycystic ovary syndrome (PCOS) treatment market. Additionally, growing awareness among the patient population about the availability of the treatment are fuelling growth of the polycystic ovary syndrome (PCOS) treatment market. The PCOS might lead to obesity, hirsutism, and infertility; hence, the awareness level in the people is increasing. This factor is boosting adoption of the polycystic ovary syndrome (PCOS) treatments and likely to fuel the polycystic ovary syndrome (PCOS) treatment market. Also, growing adoption of combination drugs coupled with rising adoption among the patients is expected to boost the global revenue of the polycystic ovary syndrome (PCOS) treatment market.

Market Restraints

Factors such as side effects associated with drugs such as weight gain, cardiovascular risks, increase insulin resistance, abnormal glucose tolerance, and thromboembolic events and Lack of drugs approved by regulatory bodies such as FDA (Food and Drug Administration) among many countries is a key factor hampering the growth of the polycystic ovarian syndrome treatment market.are expected to restrict the market growth during the forecast period

COVID-19 impact on "APAC Polycystic Ovarian Syndrome (PCOS / PCOD) Treatment Market

Various gynaecological procedures and nonessential treatment have been postponed owing to the current pandemic. Furthermore, non-COVID-19 related research is being delayed by various companies, which is leading to delayed product launches. Some disruptions in sourcing raw materials from impacted countries, such as China, were also observed in early 2020, but such disorders are unlikely to affect going forward. However, as previous restrictions are now being relaxed in several countries, the market growth will also resume.

Competitive Landscape

Key Players

The major market players are focusing on symptomatic treatments and several have their drugs in clinical trials, but not approved for marketing. There is a growing focus on surgeries, for which many medical devices are inclined towards. Some of the major players in the market are Bayer AG, Ferring BV, Merck KGaA, Novartis, Pfizer, and Takeda, Teva Pharmaceutical Industries Limited, among others.

Products in Pipeline

A detailed picture of the Polycystic ovary syndrome pipeline landscape is provided which includes the disease overview and Polycystic ovary syndrome treatment guidelines. The assessment part of the report embraces, in depth Polycystic ovary syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Polycystic ovary syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Notable Recent Deals

EvotecSE andBayer AG announced the expansion of their partnership in womens health indications with a new five-year, multi-target collaboration with participation from Celmatix Inc. to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (PCOS). Under the terms of the agreement, both companies will contribute drug targets and a comprehensive set of high-quality technology platforms to jointly develop innovative treatment options.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

There is a good growth potential in emerging markets and pharmaceutical drugs manufacturers are focusing on emerging economies in theAsia Pacificto target a large patient population. Also, effective reimbursement policies and reduction in the costs of drugs used for the treatment of PCOS is likely to increase the adoption of PCOS drugs across the Asia-Pacific region.